HealthcareAug 11, 2026

Seqirus

Company Profile Analysis

Book Demo Register Your Interest

Year Founded & Workforce

2014-12-31

5,000 Employees

Industry

Healthcare

Services

Seqirus Overview

Company Headquarters: Maidenhead, UK

Founded: 2015

Workforce: ~1001-5000

Company Working: Seqirus was established in July 2015, following the Commonwealth Serum Laboratories (CSL)’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. Seqirus is one of the world’s largest influenza vaccine companies and is one of the major partners in the prevention and control of influenza globally. The company is a reliable supplier of influenza vaccine for northern and southern hemisphere markets. Each Seqirus facility provides pandemic preparedness to their host countries as well as other countries in their respective regions.

Seqirus utilizes both egg-based and cell-culture based manufacturing technologies as well as a proprietary adjuvant for vaccine production. The company has leading R&D capabilities, a broad and differentiated product portfolio, and commercial operations in more than 20 countries. In Australia and the Asia-Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals.

Strategy

Seqirus’s vision is to protect the world from influenza. The company has built an active global business that serves significant public health needs. It has one of the broadest and most differentiated influenza vaccine portfolios in the industry. The ongoing shift in product mix from standard trivalent influenza vaccines to cell-based quadrivalent and adjuvanted products is a significant driver for the growth of this company.

Company Snapshot

$7,915M

Revenue

5,000

Employees

2014-12-31

Founded

Maidenhead, UK

Headquarters

SWOT Analysis

Strengths

High customer satisfaction
Strong distribution network

Weaknesses

Counterfeit products in the market might affect brand image

Opportunities

Increasing global footprint through mergers and acquisitions

Threats

Foreign currency exchange rate fluctuations

Key Developments

Date	Approach	Development
November 2018	Expansion	Seqirus announced an expansion of its Holly Springs manufacturing facility in North Carolina worth USD 140 million to meet the growing demand for innovative cell-based influenza vaccines. The expansion was aimed to increase the capacity for formulation and fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
October 2018	Approval	Seqirus received the FDA Approval of Afluria Quadrivalent (Influenza Vaccine) for children (six months) and older people in the US.
August 2018	Approval	Seqirus announced FDA approval of its next-generation cell-based manufacturing process at Holly Springs, North Carolina. The approval will enable Seqirus to double current production levels of Flucelvax Quadrivalent for supply in the 2019/20 influenza season.
June 2017	Advancement	Seqirus has successfully produced a cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells rather than in eggs.

Product Offering

Seqirus
- Influenza Vaccine
- Pre-Pandemic Influenza Vaccine
- Pandemic Vaccines

Financial Performance

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

USD299

Get Contacts

About the Author

Wantstats Research Team

Wantstats' research desk profiles Seqirus as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Seqirus

Company Headquarters: Maidenhead, UK Founded: 2015 Workforce: ~1001-5000 Company Working: Seqirus was established in July 2015, following the Commonwealth Serum Laboratories (CSL)’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. Seqirus is one of the world’s largest influenza vaccine companies and is one of the major partners in the prevention and control of influenza globally. The company is a reliable supplier of influenza vaccine for northern and southern hemisphere markets. Each Seqirus facility provides pandemic preparedness to their host countries as well as other countries in their respective regions. Seqirus utilizes both egg-based and cell-culture based manufacturing technologies as well as a proprietary adjuvant for vaccine production. The company has leading R&D capabilities, a broad and differentiated product portfolio, and commercial operations in more than 20 countries. In Australia and the Asia-Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals.

Starting from

$299